Turning the tables on the cholera pathogen

June 13, 2018, Harvard University
Turning the tables on the cholera pathogen
This plate assay shows how normal L. lactis bacteria (top row) can suppress the growth of V. cholera (bottom row). Normal L. lactis bacteria (upper left circle) acidify the medium around them (yellow color) and hinder V. cholerae (lower left circle) from growing in this area. A L. lactis mutant strain unable to acidify the medium (middle upper circle) has lost its acidifying ability and cannot suppress the pathogen anymore, whereas a repaired mutant L. lactis strain (upper right circle) both abilities again. Credit: Wyss Institute at Harvard University

Recent cholera outbreaks in regions that are ravaged by war, struck by natural disasters, or simply lack basic sanitation, such as Yemen or Haiti, are making the development of new and more effective interventions a near-term necessity. Sometimes within hours, the water- and food-borne diarrheal disease caused by the bacterium Vibrio cholerae can lead to severe dehydration, putting victims' lives at immediate risk, especially if rehydration and antibiotic therapies are not readily available or started early enough. The World Health Organization has made it a top priority to identify cholera-managing measures and a cost-effective diagnostic test to detect V. cholerae early on in individuals that may help prevent its spread.

Now, researchers at Harvard's Wyss Institute for Biologically Inspired Engineering, the Massachusetts Institutes of Technology (MIT) and Boston University, led by James J. Collins are reporting a two-pronged probiotic strategy in Science Translational Medicine that is able to suppress V. cholerae's colonization of the intestinal tract in mice and to indicate their presence by simple stool sampling. The approach's first arm leverages the ability of another bacterium normally found in certain foods, Lactococcus lactis, to create an inhospitable intestinal environment for V. cholerae, while its second arm incorporates a synthetic gene circuit into L. lactis that senses a secreted signal from V. cholerae, enabling its detection in the animals.

"Our probiotic strategy presents a conceptually new way to prevent and diagnose cholera infection. First, we harnessed a naturally occurring interaction of the cholera pathogen with the microbiome as a 'living therapeutic' and then use that interaction to engineer an organism carrying a synthetic sensing circuit as a 'living diagnostic'," said Wyss Institute Core Faculty member James Collins, Ph.D., who also is the Termeer Professor of Medical Engineering & Science at Massachusetts Institute of Technology (MIT) and a Professor of Biological Engineering at MIT. "Further translated into human conditions of V. cholerae infection, it could offer an inexpensive and extendable point-of-need intervention for managing cholera in populations at risk of outbreaks."

Collins also is faculty leader of the Wyss Institute's Living Cellular Devices initiative, which genetically re-engineers living cells as programmable devices for various biomedical applications.

Prompted by the early observation that V. cholerae bacteria are sensitive to acidic conditions, the team investigated whether L. lactis, a safe bacterium that ferments the milk sugar lactose into and used in the production of buttermilk, could be used as a probiotic intervention against V. cholerae. They demonstrated first in co-culture assays in vitro that normal L. lactis bacteria efficiently inhibited the growth of V. cholerae, while a mutant strain of L. lactis that could not produce lactic acid anymore had lost this inhibitory potential. When the researchers co-introduced L. lactis and V. cholerae into infant mice—which can be orally infected with the cholera pathogen much more easily than adult mice—they found that L. lactis significantly increased the likelihood of animals to survive the V. cholerae threat, and decreased V. cholerae's ability to thrive in mouse intestinal tissue. Again, the effect depended on L. lactis' ability to produce lactic acid, and thus to generate an inhospitable microenvironment for V. cholerae in vivo.

"The lethal dose of V. cholerae is very high. By suppressing the pathogen's development in the early phases, our approach slows the progression of the disease and wins the body valuable time to develop its own immune response to clear out the pathogen," said co-first author Ning Mao, Ph.D., who worked on the project as a graduate student in Collins' group. She now is a consultant at Simon-Kucher & Partners in their Life Science Division in Singapore. The two other co-first authors on the study are Ewen Cameron, Ph.D., a former postdoctoral fellow and expert on cholera microbiology on Collins' team who now is Senior Associate at Flagship Pioneering; and Andres Cubillos-Ruiz, Ph.D., another postdoctoral fellow working with Collins.

The team then extended their approach by using L. lactis bacteria to develop a living diagnostic. "Essentially, we used synthetic biology to make L. lactis "hear" the language that V. cholerae bacteria use to talk to themselves," said Mao. Essentially, the researchers grafted a so-called 'quorum sensing' receptor from V. cholerae for a signal called CAI-1 to L. lactis. The sensation of CAI-1 normally allows the pathogen to continuously gauge the density of its population within the intestinal microbiome. However, in the engineered L. lactis bacteria, a synthetic gene circuit links the detection of CAI-1 to parts of one of L. lactis' own signal sensing mechanisms and additional elements to enable a reporter protein to be produced only when CAI-1 is present.

In infant mice that were dosed with both, the engineered cholera-sensing L. lactis bacteria and the cholera pathogen, the team could conveniently diagnose cholera infection by tracing the activity of the reporter protein in fecal pellets of the mice. Because the engineered bacteria had a lowered capacity to create an acidic environment and actively prevent infection themselves, the team created a combined therapeutic and diagnostic probiotic intervention by treating mice with a mixture of natural and engineered L. lactis and demonstrated that it could simultaneously suppress and detect cholera infections.

"This study highlights how targeting the human gut microbiome with appropriate probiotics and engineered living cellular devices could lead to new therapeutics and diagnostics for management of infectious and epidemic diseases in many parts of the world," said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS and the Vascular Biology Program at Boston Children's Hospital, as well as Professor of Bioengineering at SEAS.

Explore further: How cholera-causing bacteria respond to pressure

More information: N. Mao el al., "Probiotic strains detect and suppress cholera in mice," Science Translational Medicine (2018). stm.sciencemag.org/lookup/doi/ … scitranslmed.aao2586

Related Stories

How cholera-causing bacteria respond to pressure

June 24, 2013
Cholera remains common in non-industrialized parts of the world today. It persists in part because V. cholera, the bacteria that causes the disease, is able to survive in diverse environments ranging from the intestinal lumen, ...

How vibrio cholera is attracted by bile revealed

April 25, 2016
A group of researchers from Osaka University, Hosei University, and Nagoya University have revealed the molecular mechanism that Vibrio cholerae, the etiological agent of cholera, is attracted by bile. This group has also ...

Cholera discovery could revolutionize antibiotic delivery

October 19, 2012
(Phys.org)—Three Simon Fraser University scientists are among six researchers who've made a discovery that could help revolutionize antibiotic treatment of deadly bacteria.

Bacterial gene 'therapy' to combat cholera

July 9, 2012
Cholera is an extremely virulent intestinal infection caused by ingestion of the bacterium Vibrio cholerae (V. cholerae). EU researchers elucidated the molecular mechanisms behind expression of virulence genes with important ...

In zebrafish, the cholera bacterium sets off a surprising flush

April 3, 2018
Researchers experimenting with live zebrafish witnessed a 200-percent increase in the strength of intestinal contractions soon after exposure to the cholera-causing bacterium Vibrio cholerae, leading to expulsion of native ...

Researchers work towards pharmacological targets for cholera

January 20, 2011
Just over a year after the earthquake in Haiti killed 222,000 people there's a new problem that is killing Haitians. A cholera outbreak has doctors in the area scrambling and the water-borne illness has already claimed 3600 ...

Recommended for you

Evidence that addictive behaviors have strong links with ancient retroviral infection

September 24, 2018
New research from an international team led by Oxford University's Department of Zoology and the National-Kapodistrian University of Athens, published today in Proceedings of the National Academy of Sciences (PNAS), shows ...

Taking a catnap? Mouse mutation shown to increase need for sleep

September 24, 2018
Sleep is vital for adequate functioning across the animal kingdom, but little is known about the physiological mechanisms that regulate it, or the reasons for natural variation in people's sleep patterns.

Know someone sick? Your own smell might give it away

September 24, 2018
Odors surround us, providing cues about many aspects of personal identity, including health status. Now, research from the Monell Center extends the scope and significance of personal odors as a source of information about ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Reconstructing healthy liver cells using a nanomaterial-based matrix 

September 24, 2018
NUS pharmaceutical scientists, together with clinicians from the National University Health System (NUHS), have developed a nanomaterial-based hydrogel that encourages amniotic epithelial cells (a type of stem cell) to grow ...

Japanese team creates human oogonia using human stem cells in artificial mouse ovaries

September 21, 2018
A team of researchers with members from several institutions in Japan has successfully generated human oogonia inside of artificial mouse ovaries using human stem cells. In their paper published in the journal Science, the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.